

## New Brief Pulse ECT with *Computer-Assisted* Easy Seizure Monitoring



### Somatics Thymatron™ DGx

- Automatically monitors your choice of EEG-EEG, EEG-ECG, or EEG-EMG and determines EEG and motor seizure lengths.
- Computer-measured seizure quality, including postictal EEG suppression, seizure energy index.
- Up to 8 seconds stimulus duration; pulsewidth as short as 0.5 ms.
- Single dial sets stimulus charge by age; high-dose option available.
- FlexDial™ adjusts pulsewidth and frequency without altering dose.

Distributed in the U.K. by:  
DANTEC Electronics, Ltd.  
Garonor Way  
Royal Portbury  
Bristol BS20 9XE  
TEL (44) 1275-375333  
FAX (44) 1275-375336

Distributed in Australia by:  
MEECO Holdings Pty. Ltd.  
10 Seville St.  
North Parramatta NSW 2151  
Australia  
TEL (61) 2630-7755  
FAX (61) 2630-7365

Distributed in New Zealand by:  
WATSON VICTOR, Ltd.  
4 Adelaide Rd.  
Wellington, New Zealand  
TEL (64) 4-385-7699  
FAX (64) 4-384-4651

Distributed in India by:  
DIAGNO.SYS  
New Delhi  
TEL (91) 11-644-0546  
FAX (91) 11-622-9229

Distributed in Pakistan by:  
IQBAL & CO.  
Islamabad  
TEL (92) 51-291078  
FAX (92) 51-281623

Distributed in South Africa by:  
DELTA SURGICAL  
Craighall  
TEL (27) 11-792-6120  
FAX (27) 11-792-6926

Distributed in U.S.A. and Canada by:

 **SOMATICS, INC., 910 Sherwood Drive # 17, Lake Bluff, IL, 60044, U.S.A.**  
Fax: (847) 234-6763; Tel: (847) 234-6761

# REASON TO BE CHEERFUL



## LUSTRAL™ 50mg

sertraline



Established in treating depression



**Abbreviated Prescribing Information:** LUSTRAL™ (sertraline) **Presentation:** Tablets containing 50mg or 100mg sertraline. **Indications:** Treatment of symptoms of depressive illness and accompanying symptoms of anxiety. Prevention of relapse or recurrence of depressive episodes including accompanying symptoms of anxiety. **Dosage:** LUSTRAL should be given as a single daily dose. The initial dose is 50mg and the usual therapeutic dose is 50mg daily. Dosage can be further increased, if appropriate, to 150mg or a maximum of 200mg daily. Patients should be maintained on the lowest effective dose and doses of 150mg or more should not be used for periods exceeding 8 weeks. **Use in children:** Not recommended. **Use in the elderly:** Usual adult dose. **Contra-indications:**

Hypersensitivity to LUSTRAL. Hepatic insufficiency. **Use during pregnancy:** LUSTRAL should be used only if clearly needed. **Lactation:** Not recommended. **Precautions, warnings:** Renal insufficiency, unstable epilepsy, ECT, driving. LUSTRAL should be discontinued in a patient who develops seizures. LUSTRAL should not be administered to patients concurrently being treated with tranquilizers who drive or operate machinery. Do not use with, or within two weeks of ending treatment with, MAOIs. At least 14 days should elapse before starting any MAOI following discontinuation of LUSTRAL. Patients should be closely supervised for the possibility of suicide attempt or activation of mania/hypomania. **Drug interactions:** Administer with caution in combination with other centrally active medication. Serotonergic drugs including tryptophan, sumatriptan and fenfluramine should not be used with LUSTRAL. It is recommended that plasma lithium levels be monitored following initiation of LUSTRAL. Although LUSTRAL has been shown to have no adverse interaction with alcohol, concomitant use with alcohol is not recommended. The potential for LUSTRAL to interact with other highly protein bound drugs should be borne

in mind. The potential of LUSTRAL to interact with e.g. warfarin, diazepam, tolbutamide and cimetidine has not been fully assessed. With warfarin prothrombin time should be monitored when LUSTRAL is initiated or stopped. **Side-effects:** Dry mouth, nausea, diarrhoea/loose stools; ejaculatory delay, tremor, increased sweating, dyspepsia, dizziness, insomnia and somnolence. Asymptomatic elevations in serum transaminases have been reported infrequently (approx. 0.8%) in association with LUSTRAL. These usually occurred within the first 9 weeks treatment and resolved on cessation of therapy. Malaise and rash have been reported. Seizures (see precautions, warnings). There have been isolated reports of movement disorders and rare cases of hyponatraemia. **Legal category:** POM. **Basic NHS cost:** 50mg tablet (PL 57/0308) Calendar pack of 28, £26.51; 100mg tablet (PL 57/0309) Calendar pack of 28, £39.77. Further information on request. Invicta™ Pharmaceuticals or Richborough™ Pharmaceuticals Divisions of Pfizer Limited, Sandwich, Kent.

